A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

G. Giaccone, E. F. Smit, J. P. Van Meerbeeck, T. Splinter, R. P. Golding, H. M. Pinedo, D. Laan, H. Van Tinteren, P. E. Postmus

Research output: Contribution to journalArticle

Abstract

Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)109-112
Number of pages4
JournalAnnals of Oncology
Volume11
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

gemcitabine
Paclitaxel
Non-Small Cell Lung Carcinoma
Outpatients
Drug Therapy

Keywords

  • Chemotherapy
  • Gemcitabine
  • Non-small-cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Giaccone, G., Smit, E. F., Van Meerbeeck, J. P., Splinter, T., Golding, R. P., Pinedo, H. M., ... Postmus, P. E. (2000). A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients. Annals of Oncology, 11(1), 109-112. https://doi.org/10.1023/A:1008321000887

A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients. / Giaccone, G.; Smit, E. F.; Van Meerbeeck, J. P.; Splinter, T.; Golding, R. P.; Pinedo, H. M.; Laan, D.; Van Tinteren, H.; Postmus, P. E.

In: Annals of Oncology, Vol. 11, No. 1, 2000, p. 109-112.

Research output: Contribution to journalArticle

Giaccone, G, Smit, EF, Van Meerbeeck, JP, Splinter, T, Golding, RP, Pinedo, HM, Laan, D, Van Tinteren, H & Postmus, PE 2000, 'A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients', Annals of Oncology, vol. 11, no. 1, pp. 109-112. https://doi.org/10.1023/A:1008321000887
Giaccone G, Smit EF, Van Meerbeeck JP, Splinter T, Golding RP, Pinedo HM et al. A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients. Annals of Oncology. 2000;11(1):109-112. https://doi.org/10.1023/A:1008321000887
Giaccone, G. ; Smit, E. F. ; Van Meerbeeck, J. P. ; Splinter, T. ; Golding, R. P. ; Pinedo, H. M. ; Laan, D. ; Van Tinteren, H. ; Postmus, P. E. / A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients. In: Annals of Oncology. 2000 ; Vol. 11, No. 1. pp. 109-112.
@article{9d6ad628e66a4b9abdc29b1f9d9410bf,
title = "A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients",
abstract = "Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24{\%} was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.",
keywords = "Chemotherapy, Gemcitabine, Non-small-cell lung cancer, Paclitaxel",
author = "G. Giaccone and Smit, {E. F.} and {Van Meerbeeck}, {J. P.} and T. Splinter and Golding, {R. P.} and Pinedo, {H. M.} and D. Laan and {Van Tinteren}, H. and Postmus, {P. E.}",
year = "2000",
doi = "10.1023/A:1008321000887",
language = "English (US)",
volume = "11",
pages = "109--112",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

AU - Giaccone, G.

AU - Smit, E. F.

AU - Van Meerbeeck, J. P.

AU - Splinter, T.

AU - Golding, R. P.

AU - Pinedo, H. M.

AU - Laan, D.

AU - Van Tinteren, H.

AU - Postmus, P. E.

PY - 2000

Y1 - 2000

N2 - Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

AB - Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

KW - Chemotherapy

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0033952737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033952737&partnerID=8YFLogxK

U2 - 10.1023/A:1008321000887

DO - 10.1023/A:1008321000887

M3 - Article

C2 - 10690398

AN - SCOPUS:0033952737

VL - 11

SP - 109

EP - 112

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -